<DOC>
	<DOCNO>NCT00955994</DOCNO>
	<brief_summary>The treatment acute pain patient irritable bowel symptom suboptimal . This placebo control study demand treatment pain experience 4 week period patient irritable bowel syndrome . Patients record severity pain take study medication two hour later .</brief_summary>
	<brief_title>Effect Asimadoline , Member New Medication Class , Acute Attacks Pain Irritable Bowel Syndrome</brief_title>
	<detailed_description>Background : Asimadoline reduce visceral sensitivity experimental animal model test effect gastric sensorimotor function healthy individual . It reduce pain sensation response distension correspond pressure frequently encounter human colon . However , effect improvement pain gastrointestinal symptom individual irritable bowel syndrome ( IBS ) unclear . Hypothesis : The kappa opioid agonist , Asimadoline , reduce pain discomfort decrease gastrointestinal symptom participant IBS . Aim The aim compare effect Asimadoline ( 0.5 mg p.r.n , 1mg q.i.d . ) placebo pain discomfort gastrointestinal symptom patient IBS . Methods : This phase IIB , single center , randomise , double-blind , placebo control study treatment pain discomfort associate IBS study medication placebo administer required relief symptom 2 tablet , 4 time per day . After 2-week run-in period characterize nature , frequency severity pain ensure eligibility study , participant treat pain episode need arises strict recommendation self-administer medication ( number , time interval etc ? ) period 4 week . No pain medication permit first 6 week ( 2 week run-in , 4 week randomize treatment ) . During study , patient collect daily data characterize pain symptom IBS , adequate relief pain/discomfort . The participant also keep track symptom medication use two week observation period last dose medication . A blood sample take DNA extract assess whether IBS patient single nucleotide polymorphism gene kappa receptor . Anticipated Results Future Directions : We anticipate demonstrate exacerbation pain IBS effectively reduce intermittent treatment medication , asimadoline . This study provide preliminary data use estimate sample size required phase III program trial several center .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Inclusion Criteria 1 . Nonpregnant , nonbreastfeeding female ; 2 . 1865 year old ; 3 . Established diagnosis IBS accord Rome II criterion . 4 . No alarm indicator clinical assessment ( weight loss 7 kg , bleeding , unexplained recent rectal bleeding uninvestigated colonoscopy double contrast barium enema flexible sigmoidoscopy pass 5 year ) . 5 . Females childbearing potential sexually active must use acceptable method contraception period least one month first dose study medication , continue duration study one month end study . Acceptable birth control method : surgical sterilization , oral implant contraceptive therapy , intrauterine device double barrier method ( diaphragm spermicidal gel foam condom contraceptive gel foam ) . Postmenopausal define &gt; 12 month since last menses . Females abstinent may participate agree use doublebarrier method contraception throughout study become sexually active . . 6 . Patients must provide write informed consent prior inclusion study . Exclusion criteria 1 . Patients abdominal pain discomfort score less 40 mm VAS great score less 4 day 14 day runin period ( &lt; 30 % day runin period ) . 2 . Patients abdominal pain discomfort score 60 mm VAS 10 day 14 day runin period ( &gt; 70 % day runin period ) . 3 . Clinically significant abnormal laboratory value screen visit 4 . Structural metabolic diseases/conditions affect gastrointestinal system . For screen Bowel Disease Questionnaire 26 follow Appendix 1 use . 5 . Unable withdraw medication runin period : Alter GI transit include laxative , antispasmodic , 5HT 3 antagonist ( e.g . alosetron , ondansetron ) , 5HT 4 agonist ( e.g . tegaserod ) , triptans ( 5HT 1B 1D agonist ) , magnesium aluminumcontaining antacid , prokinetics , erythromycin , narcotic , anticholinergic , loperamide Analgesic drug include opiate , NSAID , COX 2 inhibitor Inhibiting CYP 3A4 2D6 include carbamazepine , glucocorticoid , phenobarbital , phenytoin , rifampin , systemic antifungal drug ( e.g . ketoconazole ) Benzodiazepines NOTE : Low stable dos antidepressant , thyroid replacement , estrogen replacement , low dose aspirin cardioprotection birth control pills depot injection permissible . 6 . History positive stool culture pathogenic ova parasite enteric pathogen within past 3 month , successfully eradicate . 7 . Female patient pregnant breastfeeding . 8 . Clinical evidence ( include physical exam , ECG , laboratory test ) review medical history ) significant cardiovascular , respiratory , renal , hepatic , gastrointestinal , hematological , neurological , psychiatric , disease interfere objective study . The Hospital Anxiety Depression Scale ( HADS ) 33 use exclude patient significant affective disorder , well determine anxiety depression score start study . 9 . Patients know hypersensitive Asimadoline opioid agonist . 10 . Patients previously expose Asimadoline . 11 . Patients participate another clinical study within past 30 day . 12 . Patients consider investigator alcoholic remission know substance abuser . 13 . Previous gastric intestinal surgery ( except appendectomy , cholecystectomy hysterectomy ) . 14 . Legal incapacity limit legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>